- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
Synonyms :
Class :
methadone: they may increase the QTc-prolonging effect of QTc -prolonging agents
methadone: they may increase the QTc-prolonging effect of QTc -prolonging agents
methadone: they may increase the QTc-prolonging effect of QTc -prolonging agents
methadone: they may increase the QTc-prolonging effect of QTc -prolonging agents
methadone: they may increase the QTc-prolonging effect of QTc -prolonging agents
lemborexant may enhance the CNS depressant effect of CNS depressants
may enhance the serum concentration of CYP3A4 inhibitors
may increase the CNS depressant effect of CNS Depressants
may have an increased CNS depressant effect when combined with buprenorphine
may have an increased CNS depressant effect when combined with CNS depressants
may have an increased CNS depressive effect when combined with CNS depressants
may have an increased CNS depressive effect when combined with CNS depressants
may have an increased CNS depressive effect when combined with methotrimeprazine
may have an increased CNS depressive effect when combined with oxycodone
may have an increased CNS depressant effect when combined with flunitrazepam
may have an increased CNS depressant effect when combined with CNS depressants
calcium, magnesium, potassium and sodium oxybate
may have an increased CNS depressant effect when combined with oxybate salt products
suvorexant: they may increase the CNS depressant effect of CNS Depressants
may have an increased Effect of CNS depressant when combined with serotonergic opioids
Ropeginterferon Alfa-2b: they may increase the adverse effect of CNS Depressants
when both drugs are combined, there may be an increased risk or severity of QTC prolongation
QTc interval is increased both by lenvatinib and methadone
when both drugs are combined, there may be an increased QTC interval
may increase the QT-prolonging effect and enhance the risk of bradycardia, hypokalemia
CYP3A strong enhancers of the small intestine may reduce the bioavailability of methadone
when used together, entrectinib and methadone both increase the QTc interval
when used together, encorafenib and methadone both increase the QTc interval
may increase the QTc interval when combined
may increase the CNS depressant effect
may increase the CNS depressant effect
CNS depressants increase the effect of CNS depression of thalidomide
CNS depressants increase the efficacy of cannabinoid products
CNS depressants increase the efficacy of cannabinoid products
may increase the CNS depressant effect of bromperidol
may have an increased CNS depressive effect when combined with flunarizine
it increases the effect of CNS depressants
may have an increased CNS depressant effect when combined with orphenadrine
may have an increased CNS depressant effect when combined with CNS depressants
may have an increased CNS depressant effect when combined with paraldehyde
may increase the CNS depressant effect of flibanserin
eluxadoline: they may increase the CNS depressant effect of CNS Depressants
may enhance the risk of adverse/toxic effect of other CNS depressants
may enhance the risk of adverse/toxic effect of other CNS depressants
may enhance the risk of adverse/toxic effect of other CNS depressants
may enhance the risk of adverse/toxic effect of other CNS depressants
may enhance the risk of adverse/toxic effect of other CNS depressants
may reduce the analgesic effect of Opioid agonists
may reduce the analgesic effect of Opioid agonists
may reduce the analgesic effect of Opioid agonists
may reduce the analgesic effect of Opioid agonists
may have an increased CNS depressive effect when combined with cannabinoid-containing products
may have an increased CNS depressive effect when combined with cannabinoid-containing products
methadone: they may diminish the serum concentration of CYP3A4 Inducers
methadone: they may diminish the serum concentration of CYP3A4 Inducers
methadone: they may diminish the serum concentration of CYP3A4 Inducers
methadone: they may diminish the serum concentration of CYP3A4 Inducers
methadone: they may diminish the serum concentration of CYP3A4 Inducers
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the risk of adverse effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the CNS depressant effect
may reduce the therapeutic effect
may reduce the therapeutic effect
may reduce the therapeutic effect
methadone concentration serum may be enhanced by aromatase inhibitors
methadone concentration serum may be enhanced by aromatase inhibitors
methadone concentration serum may be enhanced by aromatase inhibitors
methadone concentration serum may be enhanced by aromatase inhibitors
may decrease the therapeutic effect when combined with lubiprostone
Combining methadone with pranlukast may cause a reduction in the methadone’s metabolism
the effect of methadone is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
exemestane (aromatase inhibitors) may decrease the serum concentration of methadone
Aromatase inhibitors may enhance the serum concentration of methadone
Aromatase inhibitors may enhance the serum concentration of methadone
May reduce the therapeutic efficacy of tipranavir
CNS Depressants may enhance the CNS depressant effect of brexanolone
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
CNS depressants increase the effect of sedation of ropinirole
may increase the CNS depressant effect
may enhance the risk of adverse/toxic effect of other CNS depressants
may enhance the risk of adverse/toxic effect of other CNS depressants
may enhance the risk of adverse/toxic effect of other CNS depressants
may enhance the risk of adverse/toxic effect of other CNS depressants
may enhance the risk of adverse/toxic effect of other CNS depressants
may decrease the therapeutic effect of antibiotics
may have an increased CNS depressive effect when combined with brexanolone
may have an increased CNS depressive effect when combined with CNS depressants
may have an increased CNS depressive effect when combined with CNS depressants
may have an increased CNS depressive effect when combined with CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
may have an increased CNS depressant effect when combined with CNS depressants
may have an increased CNS depressant effect when combined with Cyproheptadine
may increase the toxic effect of CNS depressants
may increase the adverse effect of CNS Depressants
doxylamine: they may increase the CNS depressant effect of CNS Depressants
perampanel: they may increase the CNS depressant effect of CNS Depressants
valerian: they may increase the CNS depressant effect of CNS Depressants
it increases the effect of CNS depressants
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
may increase the serotonergic effects
acetaminophen/doxylamine/dextromethorphan
may increase the CNS depressant effect of Doxylamine
metoclopramide increases the effect of CNS depressants
The Therapeutic effectiveness of abacavir may be reduced by methadone
methadone concentration serum may be reduced by atazanavir
pramipexole: they may increase the sedative effect of CNS Depressants
mianserin: they may increase the CNS depressant effect of CNS Depressants
it decreases the level of methadone by inhibiting gastrointestinal absorption
it increases the effect of CNS depressants
it increases the effect of CNS depressants
it increases the effect of CNS depressants
CNS depressants increase the effect of oxycodone
it increases the toxicity of CNS depressants
CNS depressants increase the effect of zolpidem
CNS depressants increase the effect of opioid agonists
CNS depressants increase the effect of opioid agonists
CNS depressants increase the effect of opioid agonists
CNS depressants increase the effect of opioid agonists
